BioSpace News Archive

Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.

Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program

Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye, announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States.

Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare, a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, announced it has earned a spot on the 2021 Report on Business Women Lead Here list, an annual editorial benchmark to identify best-in-class executive gender diversity in corporate Canada.

At virtual Annual General Shareholders’ Meeting, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the boards’ proposals by a large majority.

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28, 2021 at 8:00 a.m. EDT . The call will be hosted by Mike Mahoney , chairman and chief executive officer, and Dan Brenna

ESSA Pharma Inc. (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Ari Brettman , M.D., has stepped down from ESSA’s Board of Directors

China Pharma Holdings, Inc. (NYSE American: CPHI) (“China Pharma,” the “Company” or “We”), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China , today announced financial results for the fiscal year ended December 31 , 20 20 .

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $4 million dollars of expansion capital. This financing significantly strengthens the Company’s balance sheet and supports its progress in the commercialization and sale of recombinant spider silk.